FDA-approved medicines exist for specific indications

Triptorelin Acetate

GnRH agonist (D-Trp6-LHRH) — labeled oncology/endocrine depot objects; salt/depot care.

Editorial review:

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Identity lock. Triptorelin is a synthetic GnRH agonist (D-Trp6-LHRH). PubChem CID 25074470; formula C64H82N18O13 / MW 1311.4; CAS 57773-63-4 (triptorelin base; acetate / pamoate / embonate salts are formulation objects of the same peptide). Labeled oncology / endocrine objects exist in multiple jurisdictions (e.g. advanced prostate cancer androgen-deprivation; central precocious puberty; endometriosis — exact indications are label- and salt/depot-specific). This drawer marks papers for education. It is not use advice and does not replace product labeling.

Bottom line

Strongest evidence is labeled GnRH-agonist clinical use: prostate-cancer ADT reviews/updates, endometriosis treatment reviews, central precocious puberty depot data, plus PK/PD characterizations. Salt/depot differences (acetate vs pamoate/embonate; 1-month vs 3-month vs 6-month) matter for product identity. Do not treat gray-market “triptorelin acetate” vials as interchangeable with regulated depot products.

Papers

Prostate cancer / ADT

PMID 12058149 — 2002

Tested: monograph-style clinical information on triptorelin pamoate (Trelstar) as a GnRH agonist product object.

Does not show: that every acetate research vial equals the labeled pamoate depot.

PMID 20166771 — Keating 2010

Tested: review of triptorelin embonate 6-month formulation.

Does not show: acetate vial equivalence.

PMID 20969451 — Whelan 2010

Tested: triptorelin embonate 6-month formulation for prostate cancer.

Does not show: non-depot research-chemical interchangeability.

PMID 23252566 — Ploussard 2013

Tested: review of triptorelin in prostate-cancer management.

Does not show: a new primary pivotal by itself.

PMID 27246172 — Merseburger 2016

Tested: update on triptorelin and androgen-deprivation therapy thinking for prostate cancer.

Does not show: consumer peptide use guidance.

Endometriosis / CPP

PMID 24832495 — Leone Roberti Maggiore 2014

Tested: review of triptorelin for endometriosis treatment.

Does not show: that unlabeled acetate equals regulated gynecologic products.

PMID 29957076 — Bertelloni 2018

Tested: triptorelin depot for central precocious puberty in children ≥2 years (labeled-population framing).

Does not show: adult wellness or bodybuilding use.

PK / PD

PMID 15822863 — Lahlou 2005

Tested: pharmacodynamics of triptorelin.

Does not show: sourcing or compounding advice.

PMID 16302716 — Lahlou 2005

Tested: pharmacokinetics and pharmacodynamics of triptorelin.

Does not show: off-label metabolic claims.

What is not established

Interchangeability of unlabeled acetate vials with labeled depot products (pamoate/embonate, multi-month microspheres). Any non-labeled “peptide fitness” use. That endometriosis or CPP labels transfer to unregulated products. This drawer does not provide use advice, schedules, or sourcing.

Selected sources

12058149 20166771 20969451 23252566 24832495 27246172 29957076 15822863 16302716

What people discuss

Reported experiences

Reported topics are not established benefits.

Watch for

Risks and unknowns

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.